Showing results (891-900 of 1,273) with videos related to

Sort By:
Pageof 128
Blood|July 1, 1990
T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complicationsK C Anderson, R Soiffer, R DeLage, et al.
Circulation|May 1, 1990
Body fat distribution and male/female differences in lipids and lipoproteinsD S Freedman, S J Jacobsen, J J Barboriak, et al.
Plos One|May 10, 2014
A high-throughput method to examine protein-nucleotide interactions identifies targets of the bacterial transcriptional regulatory protein furChunxiao Yu, Carlos A Lopez, Han Hu, et al.
Journal of Medical Internet Research|February 13, 2020
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation StudyTjalf Ziemssen, Daniela Piani-Meier, Bryan Bennett, et al.
Circulation|July 6, 2006
Lumen loss in the first year in saphenous vein grafts is predominantly a result of negative remodeling of the whole vessel rather than a result of changes in wall thicknessGeorge T Lau, Lloyd J Ridley, Paul G Bannon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Experimental Hematology|January 1, 1997
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulationS N Manié, M Sattler, A Astier, et al.
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Neurology|March 29, 2006
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP W O'Connor, D Li, M S Freedman, et al.
CNS Drugs|July 29, 2021
Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE StudyGiovanni Castelnovo, Oliver Gerlach, Mark S Freedman, et al.
Pageof 128